Attiah, B.; Alewine, G.; Easter, M.-K.; Coover, R.A.; Fahrenholtz, C.D.
Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells. Pharmaceutics 2024, 16, 371.
https://doi.org/10.3390/pharmaceutics16030371
AMA Style
Attiah B, Alewine G, Easter M-K, Coover RA, Fahrenholtz CD.
Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells. Pharmaceutics. 2024; 16(3):371.
https://doi.org/10.3390/pharmaceutics16030371
Chicago/Turabian Style
Attiah, Bashnona, Garrett Alewine, Mary-Kate Easter, Robert A. Coover, and Cale D. Fahrenholtz.
2024. "Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells" Pharmaceutics 16, no. 3: 371.
https://doi.org/10.3390/pharmaceutics16030371
APA Style
Attiah, B., Alewine, G., Easter, M.-K., Coover, R. A., & Fahrenholtz, C. D.
(2024). Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells. Pharmaceutics, 16(3), 371.
https://doi.org/10.3390/pharmaceutics16030371
